Bardoxolone methyl (CDDO-Me), an oral antioxidant and inflammation modulator that promotes the expression of NRF2 and suppresses NF-κB, has shown a significant increase in the mean estimated glomerular filtration rate (eGFR) in patients with stage 3–4 CKD and type 2 diabetes mellitus compared to a placebo at 24 weeks [162]. The gene discussed is NFE2L2; the disease is type 2 diabetes mellitus.